

Figure W1. Biochemical inhibition of endogenous AXL sensitizes cells to TRAIL. FLO-1 cells were treated with vehicle, AXL inhibitor (BMS-777607, 5 μM), TRAIL (40 ng/ml) alone or in combination with BMS-777607 for 5 hours. Cell viability was evaluated by CellTiter-Glo Luminescent Cell Viability Assay. Inhibition of AXL with BMS-777607 significantly decreased cell survival in response to TRAIL ($P < .001$).



Figure W2. Knockdown of endogenous AXL enhances TRAIL-induced cleavage of Bid. FLO-1 cells stably expressing control shRNA or AXL shRNA were treated with vehicle or TRAIL (40 ng/ml) for 5 hours and then subjected to Western blot analysis of AXL and Bid proteins. The data indicated that knockdown of AXL expression significantly increased cleavage of Bid in response to TRAIL. Gel loading was normalized for equal β-actin.



Figure W3. AXL has no significant effect on expression and localization of death receptors. (A) OE33 cells stably expressing pcDNA4 or AXL were subjected to immunofluorescence with DR5 or DR4 antibodies. Cells were then counterstained with 4′,6-diamidino-2-phenylindole (blue fluorescence) and examined by fluorescence microscopy. The data indicated that the reconstitution of AXL had no significant effect on expression and localization (green fluorescence) of DR5 and DR4 death receptors. Representative 40× magnification images are shown. (B) Western blot analysis of AXL and DcR1 proteins in OE33 cells stably expressing pcDNA4 or AXL. The data indicated that the reconstitution of AXL had no effect on DcR1 protein expression. Gel loading was normalized for equal β-actin.



Figure W4. AXL has no significant positive effect on FLIP expression or FLIP/FADD protein association. (A) OE33 cells stably expressing pcDNA4 or AXL were treated with vehicle or TRAIL (40 ng/ml) for 5 hours and then subjected to Western blot analysis of AXL and FLIP proteins. The data indicated that AXL expression alone or in combination with TRAIL had no significant effect on FLIP protein levels. (B) Western blot analysis of control IgG or FLIP immunoprecipitates in OE33/pcDNA4 or OE33/AXL cells following treatment with TRAIL (40 ng/ml) for 5 hours. The data showed that the reconstitution of AXL in OE33 cells reduced FLIP/FADD interaction in response to TRAIL; *, non-specific protein band. Gel loading was normalized for equal β-actin.



Figure W5. AXL and DR4 are associated in a protein complex. Western blot analysis of immunoprecipitated proteins with control IgG or DR4 antibodies in OE33 cells stably expressing AXL without treatment with TRAIL. The data indicated protein interaction between AXL and DR4 independent of TRAIL.